Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
Status:
Closed
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
S1400B is closed to accrual effective December 12, 2016, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490